Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q2 2018 · 10-Q
Revenue$604.00K$604.00K−1.1% vs Q2 2017 Net Income-$2.92M-$2.92MN/M vs Q2 2017 EPS Diluted$0.20$0.20−16.7% vs Q2 2017 Operating Income-$3,111,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-515.1%+35.7 pt vs Q2 2017
Net margin-482.8%+38.2 pt vs Q2 2017
ended Feb 28, 2018 · filed Apr 9, 2018 · 40 d after period end